PRFX vs. ALLR, ATNF, QLGN, INM, PXMD, NBSE, CMND, BPTH, GLMD, and LSDI
Should you be buying PainReform stock or one of its competitors? The main competitors of PainReform include Allarity Therapeutics (ALLR), 180 Life Sciences (ATNF), Qualigen Therapeutics (QLGN), InMed Pharmaceuticals (INM), PaxMedica (PXMD), NeuBase Therapeutics (NBSE), Clearmind Medicine (CMND), Bio-Path (BPTH), Galmed Pharmaceuticals (GLMD), and Lucy Scientific Discovery (LSDI). These companies are all part of the "pharmaceutical preparations" industry.
PainReform (NASDAQ:PRFX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, community ranking, dividends, profitability, earnings, valuation and media sentiment.
PainReform has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
37.3% of PainReform shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 0.0% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Allarity Therapeutics had 1 more articles in the media than PainReform. MarketBeat recorded 4 mentions for Allarity Therapeutics and 3 mentions for PainReform. PainReform's average media sentiment score of 0.96 beat Allarity Therapeutics' score of 0.41 indicating that PainReform is being referred to more favorably in the media.
PainReform received 1 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave PainReform an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote.
Summary
PainReform beats Allarity Therapeutics on 8 of the 9 factors compared between the two stocks.
Get PainReform News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PainReform Competitors List
Related Companies and Tools
